DUBLIN--(BUSINESS WIRE)--The "Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ResearchAndMarkets.com's offering.
This report on the global macular degeneration treatment market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on disease indication, drug class, distribution channel, and region.
A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and company profiles with business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global macular degeneration treatment market.
Key Segments
Based on disease indication, the global macular degeneration treatment market has been segmented into dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), and others. In terms of drug class, the market has been classified into anti-vascular endothelial growth factor and others. Based on distribution channel, the market has been categorized into hospitals, ophthalmic clinics, and ambulatory surgical centers.
The global macular degeneration treatment market has been analyzed based on increasing regulatory scrutiny, technology trends, expenditure on emerging technologies, pipeline molecules and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Regional Outlook
In terms of region, the global macular degeneration treatment market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa).
Market size and forecast for each of these regions and their key countries have been provided for the period of 2016 to 2026, along with their respective CAGRs for the forecast period 2018-2026, considering 2017 as the base year.
Key Topics Covered
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Macular Degeneration Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Growing prevalence of AMD owing to increase in the geriatric population
4.3.1.2. Increase in health care spending and improvement in health care infrastructure
4.3.1.3. New product launches and high annual cost of therapy (ACOT)
4.3.1.4. Rise in number of eye care centers leading to increased product utilization
4.3.2. Restraints
4.3.2.1. Patent expiry of three well-established anti-VEGFs
4.3.2.2. Non-compliance with treatment
4.3.2.3. Lack of awareness
4.3.3. Opportunities
4.4. Global Macular Degeneration Treatment Market Analysis and Forecast, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by Region/Globally
5.2. Key Mergers & Acquisitions
5.3. AMD Clinical Trial Analysis
5.4. Reimbursement Scenario
5.5. AMD Prevalence Rate Globally with Key Countries
6. Global Macular Degeneration Treatment Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016-2026
6.3.1. Wet age-related macular degeneration
6.3.2. Dry age-related macular degeneration
6.3.3. Others
6.4. Global Macular Degeneration Treatment Market Attractiveness, by Disease Indication
7. Global Macular Degeneration Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016-2026
7.3.1. Anti-vascular endothelial growth factor
7.3.2. Others
7.4. Global Macular Degeneration Treatment Market Attractiveness, by Drug Class
8. Global Macular Degeneration Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Global Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016-2026
8.3.1. Hospitals
8.3.2. Ophthalmic Clinics
8.3.3. Ambulatory Surgical Centers
8.4. Global Macular Degeneration Treatment Market Attractiveness, by Distribution Channel
9. Global Macular Degeneration Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Macular Degeneration Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Macular Degeneration Treatment Market Attractiveness, by Region
10. North America Macular Degeneration Treatment Market Analysis and Forecast
11. Europe Macular Degeneration Treatment Market Analysis and Forecast
12. Asia-Pacific Macular Degeneration Treatment Market Analysis and Forecast
13. Latin America Macular Degeneration Treatment Market Analysis and Forecast
14. Middle East & Africa Macular Degeneration Treatment Market Analysis and Forecast
15. Competition Landscape
15.1. Market Player - Market Share Analysis by Company & Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. Allergan plc
15.2.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.1.2. Business Overview
15.2.1.3. Product Portfolio
15.2.1.4. Financial Overview
15.2.1.5. SWOT Analysis
15.2.2. Novartis AG
15.2.3. Pfizer Inc.
15.2.4. Santen Pharmaceuticals Co. Ltd.
15.2.5. Valeant Pharmaceuticals International Inc.
15.2.6. Bayer AG
15.2.7. F. Hoffmann-La Roche Ltd.
15.2.8. Sanofi
15.2.9. Regeneron Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/lipkte
